TY - JOUR
T1 - Diagnostic accuracy of circular RNA for diabetes Mellitus
T2 - a systematic review and diagnostic Meta-analysis
AU - Dehghanbanadaki, Hojat
AU - Asili, Pooria
AU - Haji Ghadery, Abdolkarim
AU - Mirahmad, Maryam
AU - Dehnavi, Ali Zare
AU - Parsaei, Amirhossein
AU - Baradaran, Hamid Reza
AU - Azami, Mobin
AU - Jose Justo da Silva, Gustavo
AU - Parvan, Reza
AU - Moradi, Yousef
N1 - Acknowledgements:
We thank all our staff at the Tehran University of medical sciences and at Kurdistan University of Medical sciences who helped us in this work. We also acknowledge the papers that we used and participants in those papers.
Funding Information:
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/3/8
Y1 - 2023/3/8
N2 - Background: This study aimed to investigate the pooled diagnostic ability of circular RNA (circRNA) molecules for diabetes mellitus. Methods: We searched PubMed, Scopus, and Web of Science for relevant studies. A total of 2070 participants, including 775 diabetic patients and 1295 healthy individuals, from five studies were included in this meta-analysis. True positive, true negative, false positive, and false negative data were extracted to calculate pooled sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio, and area under the receiver operating characteristics curve. The Deeks’ funnel plot was applied for publication bias assessment, Cochran’s Q test and I2 index were applied for inter-study heterogeneity assessment. Besides, a subgroup analysis was performed for determining the source of heterogeneity between studies. P value < 0.05 was considered significance. All analysis were done by STATA version 14. Results: CircRNA presented a sensitivity of 76% (95% confidence interval [95%CI]: 66-84%), specificity of 77% (95%CI: 58-89%), positive LR of 3.25 (95%CI: 1.69–6.23), negative LR of 0.31 (95%CI: 0.21–0.46), DOR of 10.41 (95%CI: 4.26–25.41), and AUC of 0.82 (95%CI: 0.79–0.85) for diabetes mellitus detection. More specifically, hsa_circ_0054633 showed a sensitivity of 67% (95%CI: 53-81%) and a specificity of 82% (95%CI: 63-100%). Conclusion: CircRNAs show highly accurate diagnostic capability for type 2 diabetes mellitus and gestational diabetes mellitus. High sensitivity of circRNAs introduces them as potential noninvasive biomarkers for early diagnosis of diabetes mellitus and their high specificity introduces them as potential therapeutic targets by regulation of their expression.
AB - Background: This study aimed to investigate the pooled diagnostic ability of circular RNA (circRNA) molecules for diabetes mellitus. Methods: We searched PubMed, Scopus, and Web of Science for relevant studies. A total of 2070 participants, including 775 diabetic patients and 1295 healthy individuals, from five studies were included in this meta-analysis. True positive, true negative, false positive, and false negative data were extracted to calculate pooled sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio, and area under the receiver operating characteristics curve. The Deeks’ funnel plot was applied for publication bias assessment, Cochran’s Q test and I2 index were applied for inter-study heterogeneity assessment. Besides, a subgroup analysis was performed for determining the source of heterogeneity between studies. P value < 0.05 was considered significance. All analysis were done by STATA version 14. Results: CircRNA presented a sensitivity of 76% (95% confidence interval [95%CI]: 66-84%), specificity of 77% (95%CI: 58-89%), positive LR of 3.25 (95%CI: 1.69–6.23), negative LR of 0.31 (95%CI: 0.21–0.46), DOR of 10.41 (95%CI: 4.26–25.41), and AUC of 0.82 (95%CI: 0.79–0.85) for diabetes mellitus detection. More specifically, hsa_circ_0054633 showed a sensitivity of 67% (95%CI: 53-81%) and a specificity of 82% (95%CI: 63-100%). Conclusion: CircRNAs show highly accurate diagnostic capability for type 2 diabetes mellitus and gestational diabetes mellitus. High sensitivity of circRNAs introduces them as potential noninvasive biomarkers for early diagnosis of diabetes mellitus and their high specificity introduces them as potential therapeutic targets by regulation of their expression.
KW - Biomarker
KW - circRNAs
KW - Diabetes
KW - Diagnosis
KW - Meta-analysis
UR - http://www.scopus.com/inward/record.url?scp=85149685957&partnerID=8YFLogxK
U2 - 10.1186/s12920-023-01476-0
DO - 10.1186/s12920-023-01476-0
M3 - Article
C2 - 36890575
AN - SCOPUS:85149685957
VL - 16
JO - BMC Medical Genomics
JF - BMC Medical Genomics
SN - 1755-8794
IS - 1
M1 - 48
ER -